These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10390236)

  • 1. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.
    Dong Y; Zhao X; Domagala J; Drlica K
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1756-8. PubMed ID: 10390236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.
    Dong Y; Xu C; Zhao X; Domagala J; Drlica K
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2978-84. PubMed ID: 9797236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus.
    Gustafson JE; Candelaria PV; Fisher SA; Goodridge JP; Lichocik TM; McWilliams TM; Price CT; O'Brien FG; Grubb WB
    Antimicrob Agents Chemother; 1999 Apr; 43(4):990-2. PubMed ID: 10103221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.
    Lu T; Zhao X; Li X; Drlica-Wagner A; Wang JY; Domagala J; Drlica K
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2703-9. PubMed ID: 11557458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistance.
    Sulavik MC; Barg NL
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3317-9. PubMed ID: 9835538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.
    Zhou J; Dong Y; Zhao X; Lee S; Amin A; Ramaswamy S; Domagala J; Musser JM; Drlica K
    J Infect Dis; 2000 Aug; 182(2):517-25. PubMed ID: 10915083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.
    Sindelar G; Zhao X; Liew A; Dong Y; Lu T; Zhou J; Domagala J; Drlica K
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3337-43. PubMed ID: 11083637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages.
    Zhao BY; Pine R; Domagala J; Drlica K
    Antimicrob Agents Chemother; 1999 Mar; 43(3):661-6. PubMed ID: 10049284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of fluoroquinolones.
    Drlica K
    Ann Med; 2000 Dec; 32(9):585-7. PubMed ID: 11209964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure.
    Venezia RA; Domaracki BE; Evans AM; Preston KE; Graffunder EM
    J Antimicrob Chemother; 2001 Sep; 48(3):375-81. PubMed ID: 11533002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin.
    Evans ME; Titlow WB
    Antimicrob Agents Chemother; 1998 Mar; 42(3):727. PubMed ID: 9517965
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
    Metzler K; Hansen GM; Hedlin P; Harding E; Drlica K; Blondeau JM
    Int J Antimicrob Agents; 2004 Aug; 24(2):161-7. PubMed ID: 15288315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin.
    Bisognano C; Vaudaux PE; Lew DP; Ng EY; Hooper DC
    Antimicrob Agents Chemother; 1997 May; 41(5):906-13. PubMed ID: 9145842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone resistance among methicillin-resistant staphylococci after usage of fluoroquinolones other than ciprofloxacin in Taiwan.
    Chang SC; Hsieh WC; Luh KT
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):143-7. PubMed ID: 7820993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Smith KR; Cobbs CG
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.